Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tezepelumab Clear all
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Terminated Phase 3 Interventional Results available

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT05398263
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Newport Beach, California • Denver, Colorado • Newark, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Tezepelumab COPD Exacerbation Study

NCT04039113
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
74
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

NCT02054130
View directory record Official record
Conditions
Asthma
Interventions
Placebo, MEDI9929 70 mg, MEDI9929 210 mg, MEDI9929 280 mg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Miami, Florida • Oviedo, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

NCT02525094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI9929, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
North Miami Beach, Florida • Tampa, Florida • Arlington Hts, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

NCT07015996
View directory record Official record
Conditions
Peanut Allergy
Interventions
Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
72
States / cities
Foley, Alabama • Mobile, Alabama • Sheffield, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

NCT02237196
View directory record Official record
Conditions
Cat Allergy, Cat Hypersensitivity
Interventions
AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT05274815
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Newport Beach, California • Newark, Delaware • Loxahatchee Groves, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 11 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 1:30 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

NCT03347279
View directory record Official record
Conditions
Asthma
Interventions
Experimental: Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
95
States / cities
Dothan, Alabama • Foley, Alabama • Gilbert, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

NCT03706079
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
13 Years to 81 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Dothan, Alabama • Gilbert, Arizona • Bakersfield, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 5, 2026, 1:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT03406078
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
21
States / cities
Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 5, 2026, 1:30 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Tezepelumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Chicago, Illinois • Chestnut Hill, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 5, 2026, 1:30 AM EDT